Therefore, ICB therapy to each receptor will modulate T cell responses in a non-redundant manner, with anti-CTLA-4 primarily affecting the priming of T cells and anti-PD-1 enhancing T cell activity in the periphery and tumor microenvironment. This evidence concerns the gene CTLA4 and neoplasm.